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Trigonelline, a component of green coffee
beans (about 1%) is a product of thermal decom-
position, formed during the coffee roasting
process. Evaluated compounds: 1-methylpyridini-
um (1-MP) and 1,4-dimethylpyridinium (1,4-
DMP) are the degradation products of trigonelline
and for many years they have been a subject of
increased interest because of theirs potential
hepatoprotective, vasoprotective and antioxidant
activity (1-5). Furthermore, some pyridinium salts
are known from cytotoxic activity against tumor
cells and this effect is probably related to their
redox properties (6, 7). 
To characterize properties of 1-MP and 1,4-
DMP, the structure and surface activity of these
compounds were investigated using surface-
enhanced Raman spectroscopy (SERS) (8).
Recently, liquid chromatographyñmass spectrome-
try method was developed to determine the concen-
tration of 1,4-DMP in rat plasma (9), and this tech-
nique was also used for food-derived bioactive
pyridines quantification, among them 1-MP and
their metabolites in human plasma and urine. The
method was applied to monitor the plasma appear-
ance and the urinary excretion, and to calculate the
pharmacokinetic parameters of the studied com-
pounds (10, 11). To our knowledge there is no
described method for simultaneous determination of
1-MP and 1,4-DMP in complex biological samples,
like e.g., tissue homogenates.
The aim of this study was to develop and vali-
date a selective and sensitive bioanalytical
LC/MS/MS method for simultaneous quantification
of 1-MP and 1,4-DMP in rat plasma and tissue
homogenates according to EMA requirements, and
finally to assess the pharmacokinetics and bioavail-
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was developed. Chromatographic separation was performed on an Aquasil C18 analytical column with an iso-
cratic elution of acetonitrile and water, both with an addition of formic acid (0.1%, v/v). Detection was achieved
by triple quadrupole mass spectrometer TSQ Quantum Ultra equipped with a heated electrospray ionization
source (HESI). The limit of quantification for both compounds was 0.05 µg/mL in plasma and 0.25 µg/g in stud-
ied tissues. The method was applied to pharmacokinetics and bioavailability of both 1-MP and 1,4-DMP with
tissue distribution of 1,4-DMP in rats. Pharmacokinetic studies of 1-MP and 1,4-DMP were carried out fol-
lowing their intravenous or intragastric administration to male Wistar rats at the dose of 100 mg/kg. The ter-
minal half-lives of 1-MP and 1,4-DMP after their intravenous administration were 55.3 and 70.8 min, respec-
tively. The absolute bioavailability was 51 and 31% for 1-MP and 1,4-DMP, respectively. 
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ability of 1-MP and 1,4-DMP considering tissue dis-
tribution of 1,4-DMP. 
EXPERIMENTAL
Reagents
The 1-methylpyridinium (1-MP) chloride, 1,4-
dimethylpyridinium (1,4-DMP) chloride and their
stable isotope labeled internal standards: 1-d3-
methylpyridinium 1-MP-d3) chloride and 1-d3-
methyl-4-methylpyridinium (1,4-DMP-d3) chloride
were provided by dr. J. Adamus from the Institute of
Applied Radiation Chemistry, Technical University
(Poland). HPLC grade acetonitrile was purchased
from J.T. Baker (Germany) and formic acid from
Fluka (Germany). Sodium phosphate dibasic, potas-
sium dihydrogen phosphate and sodium chloride
were purchased from Sigma-Aldrich (USA).
Deionized water was obtained from Millipore sys-
tem (Direct-Q 3UV, Millipore) and used in all aque-
ous solutions.
Samples 
Plasma and tissues were obtained from adult
eight-weeks old male Wistar rats (180-220 g)
(Charles River Laboratory, Germany). Rats were
injected intraperitoneally with thiopental (60 mg/kg)
and blood was collected into heparinized vials after
decapitation. The plasma samples were separated by
centrifugation (900 ◊ g, 15 min) and stored at -20OC
until used. The tissues: liver, lungs, heart, brain,
small intestine and kidney were collected, rinsed
with phosphate buffer saline solution (PBS, pH =
7.4) and stored at -80OC until used. A piece of
thawed tissue was weighted (approximately 100 mg)
and homogenized by an UltraTurraxÆ T10 basic
homogenizer (IKA, Germany) in 500 µL of PBS
solution (ratio 1 : 5, w/v). The tissue homogenates
were prepared directly before the analysis. 
Liquid chromatography conditions
The liquid chromatography system UltiMate
3000 (Dionex, USA) consisted of a pump (DGP
3600RS), a column compartment (TCC 3000RS), an
autosampler (WPS-3000TRS) and SRD-3600 sol-
vent rack (degasser) was used. Chromatographic
separation was carried out on an Aquasil C18 ana-
lytical column (4.6 ◊ 150 mm, 5 µm, Thermo
Scientific, USA) with the oven temperature set at
30OC. Acetonitrile (A) and water (B), both with a
0.1% (v/v) of formic acid addition were used as
mobile phases. Separation of analytes and IS was
performed under isocratic condition (A : B; 40 : 60,
v/v) at a flow rate of 0.8 mL/min. The autosampler
temperature was set at 10OC and the injection vol-
ume was 10 µL. The eluent from the HPLC before
being directed into the heated electrospray ioniza-
tion (HESI) probe was split in the proportion of 1 to
2 (1 part to the mass spectrometer and 2 parts to
waste). The whole HPLC analysis lasted 10 min. 
Mass spectrometric conditions
Mass spectrometric detection was performed
on TSQ Quantum Ultra triple quadrupole mass spec-
trometer (Thermo Scientific, USA) equipped with a
HESI II probe operating in the positive ion mode.
Quantification was done using selected reaction
monitoring (SRM) mode to monitor precursor →
product ion transitions of m/z 94 → 79 for 1-MP,
m/z 97 → 79 for 1-MP-d3, m/z 108 → 93 for 1,4-
DMP and m/z 111 → 93 for 1,4-DMP-d3. Data
acquisition and processing were accomplished using
Xcalibur 2.1 software (Thermo Scientific, USA).
The ion source parameters for all analytes were
as follows: ion spray voltage 4000 V, vaporizer
temperature 250OC, sheath gas and auxiliary gas
(nitrogen) pressure 30 and 10 arbitrary units, respec-
tively, and capillary temperature 350OC. Argon pres-
sure in the collision cell was 1.5 mTorr. Collision
energy was set at 23 V for 1-MP, 22 V for 1-MP-d3
and 30 V for 1,4-DMP and 1,4-DMP-d3.
Preparation of standard solutions
Stock solutions (1 mg/mL) of 1-MP chloride,
1,4-DMP chloride and its deutered analogs: 1-MP-d3
chloride and 1,4-DMP-d3 chloride were individually
prepared in ultrapure water. The combined standard
solution of 1-MP and 1,4-DMP was prepared by
mixing and diluting the appropriate amounts from
individual stock solutions. The final concentration
of the working standard solutions was 50, 40, 35, 30,
25, 20, 10, 5, 1.5, 1 and 0.5 µg/mL. Internal standard
(IS) solution consisted of 1-MP-d3 and 1,4-DMP-d3
at a concentration of 25 µg/mL. IS solution was pre-
pared by mixing and diluting the appropriate
amounts from individual stock solutions. All stock
and working solutions were stored at 4OC until used.
Preparation of calibration and quality control
samples
Calibration standards (CC) and quality control
samples (QC) were prepared by spiking 10 µL of the
appropriate working mixed solution of 1-MP and
1,4-DMP chlorides into 90 µL of blank tissue
homogenate or plasma. The concentration of CC
points were equivalent to 5, 4, 3, 2, 1, 0.5, 0.1 and
0.05 µg/mL in plasma, and 25, 20, 15, 10, 5, 2.5, 0.5,
0.25 µg/g tissue in tissue samples. Concentration of
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QC samples were as follows: limit of quantification
(LOQ) at 0.05 µg/mL, low QC (LQC) at 0.15
µg/mL, medium QC (MQC) at 2.5 ng/mL and high
QC (HQC) at 3.5 ng/mL in plasma samples, and
LOQ at 0.25 µg/g, LQC at 0.75 µg/g, MQC at 12.5
µg/g and HQC at 17.5 µg/g in tissue samples, for
both analyzed compounds.
Samples preparation
All analyzed samples were prepared by the
way of deproteinization with acetonitrile (12). A
100 µL aliquot of rat plasma or homogenized tissues
was pipetted out into a polypropylene tube and
spiked with 10 µL of the working IS solution (25
µg/mL). Then, the samples were briefly mixed and
200 µL of acidified acetonitrile (0.1%, v/v) was
added. The mixture was again shaken, next, the sam-
ples were refrigerated at 4OC for 20 min, and after-
wards centrifuged at 16600 ◊ g for 15 min at 10OC.
The supernatant (100 µL) was transferred into new
tubes and evaporated to dryness at 37OC under a
gentle stream of nitrogen gas in a TurboVap evapo-
rator (Caliper Life Sciences, USA). The dry residue
was reconstituted with 100 µL of the
acetonitrile/water (50/50, v/v) mixture, and an
aliquot of 10 µL was injected into the LC/MS/MS
system.
Method validation
Method validation was carried out on blank
matrices: plasma and brain, liver, heart, kidney,
lungs, and small intestine homogenates spiked with
an appropriate amounts of 1-MP, 1,4-DMP and their
IS following the criteria of bioanalytical method val-
idation (13).
Selectivity/Specificity
The specificity of the method was evaluated by
analyzing blank matrices from six different rats.
Each blank sample was tested for interferences
using the proposed clean up procedure and chro-
matographic/mass spectrometric conditions.
Accuracy and precision
Precision was calculated in the terms of RSD
(%) by analyzing QC samples at four concentration
levels of 1-MP and 1,4-DMP (0.05, 0.15, 2.5 and 3.5
µg/mL in plasma, and 0.25, 0.75, 12.5, 17.5 µg/g in
the tissues). Accuracy was evaluated as [mean found
concentration / theoretical concentration] ◊ 100. The
criteria for acceptability of the data included accura-
cy within ± 15% deviation from the nominal values,
and precision within 15% RSD except for LOQ,
where it should not exceed ± 20%.
Within day precision and accuracy were exe-
cuted by repeated analysis (n = 5) of the samples at
different QC levels on the same day. Between days
precision and accuracy were determined by repeated
analysis on the following day. The concentration of
each QC sample was determined using the calibra-
tion curve prepared and analyzed on the same day.
Matrix effect and extraction recovery
The relative matrix effect was estimated
according to Matuszewski (14, 15) by assessing the
variability of standard line slopes expressed as a
coefficient of variation, RSD (%). The precision val-
ues of standard slope lines should not exceed 4% for
the method to be considered reliable, and free from
the relative matrix effect. For evaluation of the rela-
tive matrix effect, five different sources of rat matri-
ces were used.
Extraction recoveries of 1-MP and 1,4-DMP
from plasma were determined at LQC and HQC.
They were calculated by comparing the mean peak
areas obtained for deproteinized QC samples with
those of blank extracts with standards added at
appropriate concentration which represented the
100% recovery value. 
Stability studies
Long-term, short-term, freeze and thaw stabili-
ty tests were performed for plasma samples. The
samples for long-term and short-term stability tests
were kept at -20OC for the period of 4 months, and at
the room temperature for a period that exceeded the
routine sample preparation time (about 5 h), respec-
tively. Post preparation stability test was carried out
for all analyzed matrices; samples were stored in
autosampler at 10OC for 24 h. A stability study was
evaluated using two concentration levels (LQC and
HQC). All stability samples were quantified using
fresh calibration curve and compared to the nominal
concentration in the sample. Samples were consid-
ered to be stable if 85-115% of the initial concentra-
tion was found. 
Pharmacokinetic study in rats 
Using the new LC/HESI-MS/MS method, pilot
pharmacokinetic studies of 1-MP and 1,4-DMP
were carried out following their intravenous or intra-
gastric administration to male eight-weeks old
Wistar rats (180-200 g). Rats were kept under con-
ditions of constant temperature (21-25OC), and rela-
tive humidity of approximately 40-65% with a stan-
dard light/dark cycles. Animals were housed in
stainless steel cages with suspended wire-mesh
floors (maximum of 5 rats per cage). They were fast-
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ed overnight and then weighted. Rats had free access
to water throughout the experimental period.
Studied compounds: 1-MP and 1,4-DMP, dissolved
in 0.9% sterile isotonic saline, at the dose of 100
mg/kg body weight were administered intravenous-
ly or intragastrically. Rats were anesthetized via i.p.
administration of thiopental (60 mg/kg) and sacri-
ficed at the following time intervals: 5, 30, 60, 120
and 240 min after 1-MP or 1,4-DMP intravenous
administration, and 10, 30, 60, 120 and 240 min
after intragastric dosing. Three rats were sampled at
every time point. Blood samples were collected into
Figure 1. Fragmentation mass spectra of 1-MP (A) and 1,4-DMP (B), collision energy 30 V
Figure 2. Extracted ion chromatograms of 1-MP (A), 1-MP-d3 (B), 1,4-DMP (C) and 1,4-DMP-d3 (D) in rat plasma (LLOQ sample)
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microfuge tubes. Plasma and selected tissues (liver,
lungs, heart, intestine, brain and kidneys) were
stored at ñ20OC and ñ80OC until used, respectively. 
Pharmacokinetic parameters were calculated
by a non-compartmental approach from the average
concentration values, using Phoenix WinNonlin
software (Certara, USA). First order elimination rate
constant (λz) was calculated by linear regression of
time versus log concentration. Next, the area under
the mean serum and tissue compound concentration
versus time curve extrapolated to infinity (AUC0→∞)
was estimated using the log-linear trapezoidal rule
(equation 1), where Cn is the concentration of last
sampling of each compound. 
Table 1. Relative matrix effect for 1-MP and 1,4-DMP.
1-MP 1,4-DMP    
Matrix Lots 
Slope R2 SD [%] Slope R2 SD [%]  
1 0.000350 1.0000 0.000351 0.9999
2 0.000318 0.9973 0.000341 1.0000
Plasma 3 0.000330 0.9998 3.5 0.000357 0.9995 2.6
4 0.000335 0.9971 0.000349 0.9998
5 0.000329 0.9992 0.000366 0.9990
1 0.000407 0.9911 0.000461 0.9993
2 0.000366 0.9981 0.000435 0.9989
Liver 3 0.000393 0.9999 4.1 0.000451 0.9997 2.2
4 0.000401 0.9941 0.000449 0.9997
5 0.000397 0.9967 0.000442 0.9979
1 0.000464 0.9977 0.000449 0.9990
2 0.000474 0.9997 0.000423 0.9979
Heart 3 0.000472 0.9998 3.4 0.000425 0.9988 4.0
4 0.000474 0.9980 0.000411 1.0000
5 0.000506 0.9991 0.000404 0.9978
1 0.000605 0.9999 0.000481 0.9975
2 0.000656 0.9998 0.000507 0.9996
Lungs 3 0.000620 0.9961 3.3 0.000497 0.9981 2.3
4 0.000647 0.9988 0.000505 0.9988
5 0.000639 0.9981 0.000511 0.9979
1 0.000572 0.9959 0.000484 0.9985
2 0.000576 0.9996 0.000462 0.9999
Kidney 3 0.000591 0.9994 2.1 0.000476 0.9985 2.1
4 0.000558 0.9993 0.000462 0.9998
5 0.000568 0.9997 0.000465 0.9996
1 0.000581 0.9971 0.000502 0.9993
2 0.000569 1.0000 0.000486 0.9989
Brain 3 0.000550 0.9984 3.7 0.000487 0.9994 3.7
4 0.000605 0.9966 0.000530 0.9967
5 0.000560 0.9996 0.000491 0.9992
1 0.000285 0.9989 0.000285 0.9972
2 0.000288 1.0000 0.000288 0.9976
Intestine 3 0.000306 0.9997 3.6 0.000306 0.9996 3.6
4 0.000278 0.9991 0.000278 0.9996
5 0.000284 0.9999 0.000284 0.9993
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Table 2. Within day accuracy (% of nominal concentration) and precision (% RSD) for 1-MP and 1,4-DMP in plasma and rat tissues (n = 5).
1-MP 1,4-DMP
Matrix QC
Mean  Accuracy Precision Mean Accuracy Precision level
concentration [%] RSD [%] concentration [%] RSD [%]
LLQC 0.053 106.6 7.9 0.050 100.2 1.4
LQC 0.140 93.2 4.6 0.140 93.1 3.1
Plasmaa
MQC 2.539 101.6 3.2 2.434 97.4 3.8
HQC 3.365 96.1 8.4 3.423 97.8 5.0
LLQC 0.238 95.0 12.9 0.254 101.4 3.4
LQC 0.678 90.3 3.6 0.668 89.0 0.6
Liverb
MQC 11.347 90.8 6.3 11.637 93.1 1.2
HQC 16.497 94.3 4.7 16.658 95.2 6.0
LLQC 0.225 89.8 3.8 0.260 104.0 6.9
LQC 0.739 98.6 8.8 0.730 97.3 4.4
Heartb
MQC 12.667 101.3 3.9 12.699 101.6 1.8
HQC 17.715 101.2 2.4 17.496 100.0 1.8
LLQC 0.242 96.7 12.3 0.238 94.9 6.0
LQC 0.693 92.3 6.2 0.690 91.9 3.5
Lungsb
MQC 11.853 94.8 6.8 11.805 94.4 2.8
HQC 16.127 92.2 4.7 16.120 92.1 2.5
LLQC 0.288 115.0 2.9 0.237 94.8 5.4
LQC 0.795 106.0 1.9 0.753 100.4 5.4
Kidneyb
MQC 13.832 110.7 1.4 13.590 108.7 1.1
HQC 18.974 108.4 3.4 18.693 106.8 3.8
LLQC 0.242 96.7 9.3 0.248 99.1 15.4
LQC 0.750 100.0 5.4 0.779 103.8 8.9
Brainb
MQC 13.087 104.7 2.2 13.303 106.4 3.3
HQC 17.289 98.8 1.9 17.882 102.2 3.2
LLQC 0.245 97.8 5.8 0.206 82.3 0.2
LQC 0.679 90.6 2.4 0.700 93.3 5.7
Intestineb
MQC 12.181 97.4 4.2 13.249 106.0 4.9
HQC 16.419 93.8 3.1 17.943 102.5 7.8
a Mean concentration [µg/mL], b mean concentration [µg/g].
Figure 3. Plasma concentration-time profile of 1-MP after a single intravenous (●) or intragastric (■) administration to rats at the dose of
100 mg/kg
Quantification and pharmacokinetics of 1-methylpyridinium and 1,4-dimethylpyridinium... 1117
Table 3. Accuracy (% of nominal concentration) and precision (%RSD) between days for 1-MP and 1,4-DMP in plasma and rat tissues.
1-MP 1,4-DMP
Matrix QC
Mean  Accuracy Precision Mean Accuracy Precision level
concentration [%] RSD [%] concentration [%] RSD [%]
LLQC 0.051 102.2 8.6 0.0499 99.7 5.0
LQC 0.148. 99.1 7.6 0.150 100.2 8.1
Plasmaa
MQC 2.607 104.3 4.8 2.574 103.0 7.2
HQC 3.531 100.9 10.1 3.597 102.8 7.6
LLQC 0.235 94.1 9.2 0.262 104.6 5.8
LQC 0.720 96.0 9.6 0.675 90.0 2.8
Liverb
MQC 11.879 95.0 8.5 11.945 95.6 4.5
HQC 16.324 93.3 5.1 17.014 97.2 4.6
LLQC 0.197 94.6 11.3 0.265 105.8 6.4
LQC 0.661 101.8 8.4 0.737 98.2 5.1
Heartb
MQC 10.202 103.7 3.8 12.902 103.2 3.0
HQC 17.159 102.6 4.4 17.630 100.7 4.4
LLQC 0.252 100.5 14.4 0.249 99.4 6.2
LQC 0.733 97.7 6.9 0.738 98.3 9.2
Lungsb
MQC 12.442 99.5 7.3 12.799 102.4 8.8
HQC 16.986 97.1 6.6 17.292 98.8 7.9
LLQC 51.147 102.3 13.58 0.245 97.8 7.5
LQC 157.860 105.2 6.21 0.780 104.0 5.8
Kidneyb
MQC 2752.947 110.1 8.03 13.401 107.2 3.2
HQC 3654.619 104.4 4.95 18.297 104.6 3.5
LLQC 0.248 99.3 12.5 0.236 94.3 10.2
LQC 0.751 100.1 4.9 0.745 99.3 7.9
Brainb
MQC 13.043 104.3 3.2 12.945 103.6 4.5
HQC 17.704 101.2 5.3 17.897 102.3 4.9
LLQC 0.260 104.0 8.8 0.239 95.3 16.8
LQC 0.721 96.1 7.4 0.743 99.0 9.0
Intestineb
MQC 12.356 98.8 3.5 12.619 100.9 7.5
HQC 16.932 96.8 4.6 17.097 97.7 8.8
a Mean concentration [µg/mL], b mean concentration [µg/g].
Figure 4. Plasma concentration-time profile of 1,4-DMP after a single intravenous (●) or intragastric (■) administration to rats at the dose
of 100 mg/kg
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Table 4. Stability for 1-MP and 1,4-DMP in rat plasma.
1-MP 1,4-DMP
QC
Mean Accuracy Precision Mean Accuracy Precision level
concentration (µg/mL) [%] RSD [%] concentration (µg/mL) [%] RSD [%]
Short-term stability test
LQC 0.1463 97.5 8.7 0.151 100.6 1.5
HQC 3.135 89.6 5.7 3.141 89.7 7.5
Freeze and thaw stability test
LQC 0.1589 105.9 4.2 0.1483 98.9 6.8
HQC 3.900 111.4 2.7 3.372 96.3 3.4
Long-term stability test
LQC 0.1528 101.9 4.3 0.130 86.7 8.6
HQC 3.383 96.6 1.1 3.200 91.4 1.6
Table 5. Post-preparative stability for 1-MP and 1,4-DMP.
1-MP 1,4-DMP
Matrix QC
Mean  Accuracy Precision Mean Accuracy Precision level
concentration [%] RSD [%] concentration [%] RSD [%]
Plasmaa
LQC 0.162 108.2 10.9 0.156 103.7 4.2
HQC 3.557 101.6 3.3 3.647 104.2 2.8
Liverb
LQC 0.913 122 6.2 0.658 87.7 4.1
HQC 16.664 95 4.7 15.629 89.3 3.6
Heartb
LQC 0.606 80.8 10.9 0.667 88.9 3.7
HQC 15.731 89.9 6.0 16.081 91.9 3.2
Lungsb
LQC 0.789 105.2 9.1 0.919 122.5 5.0
HQC 17.779 101.6 4. 19.362 110.6 3.4
Kidneyb
LQC 1.012 135 3.2 0.740 98.6 6.1
HQC 18.703 107 2.4 18.388 105.1 4.7
Brainb
LQC 0.793 105.7 3.9 0.727 96.9 9.0
HQC 17.161 98.1 2.7 18.147 103.7 4.9
Intestineb
LQC 0.768 102.4 5.7 0.963 128.4 9.3
HQC 17.618 100.7 3.2 18.629 106.4 8.1
a Mean concentration [µg/mL], b mean concentration [µg/g].
Figure 5. Tissue distribution of 1,4-DMP after a single intravenous administration of compound at the single dose of 100 mg/kg in rats 
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AUC0→∞ = Σi=1
n
([ci + ci+1]/2) ∑ (ti+1 ñ ti) + cn/λz (1)
Area under the first-moment curve
(AUMC0→∞) was estimated by calculation of the
total area under the first-moment curve and extrapo-
lated area using the equation 2, where tn is the time
of last sampling.
AUMC0→∞ = Σi=1
n
((ti∑ci + ti+1∑ci+1)/2)∑
(ti+1 ñ ti) + (tn∑cn)λz + cn/λz2 (2)
Mean residence time (MRT) was calculated as:
MRT = AUMC0→∞/AUC0→∞                       (3)
Systemic clearance (Cl) was calculated as:
Cl = Div/AUC0→∞                                     (4)
Volume of distribution at steady state (Vss) was
calculated as:
Div ∑ AUMC0→∞Vss  = ñññññññññññññññ (5)(AUC0→∞ )2
where Div is an intravenous dose of studied compound,
AUMC is the area under the first moment curve, and
AUC is the area under the zero moment curve.
The absolute bioavailability (F) after the
extravascular (e.v.) administration compared to the
intravenous (i.v.) route was calculated as follows:
AUCe.v.F = ññññññññññññ (6)
AUCi.v.
RESULTS AND DISCUSSION
Validation data
The newly developed bioanalytical method for
the simultaneous analysis of 1-MP and 1,4-DMP in
rat matrices (plasma and selected tissue samples)
using LC/HESI-MS/MS technique was developed
and validated in the first step of the study. 
In order to construct the appropriate SRM
method, the most abundant parent and fragmenta-
tion ions of analyzed compounds and IS were cho-
sen (Fig. 1). Representative chromatograms from rat
plasma samples are shown in Figure 2. Retention
times are around 1.7 and 1.8 min for 1-MP and 1,4-
DMP, respectively. No significant interferences
with other endogenous molecules in sample were
observed. 
The obtained limit of detection for both com-
pounds was high and equaled 0.01 µg/mL and 0.05
µg/g in plasma and tissues, respectively. It provides
the measurement of studied analogsí concentration
Table 6. Pharmacokinetic parameters for 1,4-DMP and 1-MP after a single intravenous and intragastric administration at the dose of 100
mg/kg in rats.
Pharmacokinetics 1,4-DMP 1-MP
parameters Intravenous Intragastric Intravenous Intragastric
AUC 0→∞ [µg∑min/mL] 6.284 1.944 4.245 2.159
MRT [min] 44.34 140.28 38.81 110.58
t1/2 [min] 70.77 60.41 55.32 63.26
Cmax [µg/mL] - 11.38 - 16.91
Vss [mL/kg] 706 - 914 -
Cl [mL/min/kg] 15.91 - 23.56 -
F [%] - 31 51
Table 7. Pharmacokinetic parameters in rat tissues after a single intravenous administration of 1,4-DMP at the
dose of 100 mg/kg.
Pharmacokinetic parameters
Tissue AUC 0→∞ Cmax tmax MRT
[µg∑min/g] [µg/g] [min] [min]
Liver 305.03 243.80 30 115
Kidney 488.70 584.45 5 70
Brain 4.87 3.42 5 244
Intestine 530.16 232.92 5 157
Lungs 210.67 115.22 5 143
Heart 551.47 162.80 120 292
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in the biological samples from pharmacokinetic
experiments. The obtained results, in all matrices,
show good linearity over the entire concentration
range 0.05-5 µg/mL for plasma and 0.25-25 µg/g for
tissues. Calibration curves were generated using
weighted (1/x) linear regression analysis. The
extraction recoveries of 1-MP and 1,4-DMP in rat
plasma were 87.8 ± 8.2% and 92.9 ± 9.8%, respec-
tively. No relative matrix effect for studied com-
pounds (Table 1) was observed for five different
tested plasma lots, what can indicate, that developed
method is reliable and can be used in routine labora-
tory work. 
Precision was evaluated as repeatability (with-
in day precision) and reproducibility (between days
precision). The accuracy and precision results for all
matrices are shown in Table 2 (within day) and
Table 3 (between days). The obtained results were
within the acceptable limits established by EMA for
bioanalytical methods (13) confirming that the
method can be used for quantifying both 1-MP and
1,4-DMP compounds in the following rat tissues:
liver, lungs, heart, brain, small intestine, kidneys
and plasma.
The stability of analytes in rat plasma was
investigated under a variety of storage and process
conditions described in a previous section.
Compounds showed to be stable during storage
under various conditions (Table 4). Results of post-
preparative stability (24 h) for all tested matrices are
shown in Table 5. Moreover, results showed, that
both 1-MP and 1,4-DMP were stable in all analyzed
matrices, but not in liver and kidney. Since, prepared
samples of liver and kidney for 1-MP, and in case of
small intestine and lungs for 1,4-DMP should be
analyzed within 24 h. The validated LC/HESI-
MS/MS method was successfully used for quantifi-
cation of 1-MP and 1,4-DMP in rat plasma follow-
ing theirs intravenous or intragastric administration
at a dose of 100 mg/kg. The concentration of 1,4-
DMP in selected tissues were also determined with
desired accuracy and precision. 
Pharmacokinetic study in rats 
Blood samples during experiments were col-
lected in a regular time intervals. The mean concen-
tration ñ time profiles of 1-MP and 1,4-DMP in plas-
ma were plotted in Figures 3 and 4, respectively.
The results of the model independent pharma-
cokinetic data analysis obtained following intra-
venous or intragastric administration of 1-MP or
1,4-DMP in plasma are summarized in Table 6.
Target analogs were eliminated rather slowly with
the terminal half-life times for 1-MP equaled 55.3
min, and for 1,4-DMP equaled 70.8 min, after their
intravenous administration. The volumes of distri-
bution at the steady-state were in the range of 0.9
L/kg and 0.7 L/kg for 1-MP and 1,4-DMP, respec-
tively, and might indicate theirs intracellular dispo-
sition. The absolute bioavailability estimated based
on the AUC0→∞ calculated from time zero to infinity
yielded the values of 51% for 1-MP and 31% for
1,4-DMP, and was rather low, with the peak con-
centration occurring 60 min for 1-MP, and 120 min
for 1,4-DMP after their intragastric administration.
1,4-DMP has significant tissue distribution
which is in agreement with its high volume of distri-
bution (0.7 L/kg). Analysis showed that the highest
amount of 1,4-DMP was observed in heart, then in
kidney and small intestine, and the lowest one was
detected in brain (Fig. 5). Distribution was rapid and
the maximal concentration occurred in the most of
tissues at 5 min after administration with exception
of liver (maximum at 30 min) and heart (maximum
at 120 min) as seen in Table 7. These findings sug-
gest that 1,4-DMP is mostly distributed in heart and,
despite the fact that this compound is positively
charged in physiological pH, it can penetrate blood-
brain barrier, probably via a specific carrier system.
CONCLUSIONS
A rapid and simple LC/HESI-MS/MS method
was developed and validated for quantification of 1-
MP and 1,4-DMP in plasma and selected rat tissues.
The assay showed wide linear dynamic range of
0.05ñ5 µg/mL for plasma, and 0.25ñ25 µg/g for tis-
sues with acceptable within day and between days
accuracy and precision. The method was successful-
ly applied to assess the pharmacokinetic profiles of
1-MP and 1,4-DMP in rats after compounds intra-
venous and intragastric administration. The absolute
bioavailability in rats was estimated at 51% for 1-
MP and 31% for 1,4-DMP, respectively. The distri-
bution of 1,4-DMP in tissues was rapid with the
maximal concentration occurred at 5 min after com-
pound administration in kidney, intestine, lungs and
brain.
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